Potential application of [18F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma
Although not all lesions could be visualized, [<sup>18</sup>F]PSMA-11 PET identified multiple lesions imperceptible on [<sup>18</sup>F]FDG PET. These results display the potential additional diagnostic role of PSMA-targeted imaging in patients with RAI-R TC. Trial registration number No. EudraCT 2021-000456-19.
Authors
- Charlotte Verroken (ORCID: https://orcid.org/0000-0002-2451-9419)
- Bruno Lapauw (ORCID: https://orcid.org/0000-0002-1584-4965)
- Vanessa Schelfhout
- Bliede Van den Broeck (ORCID: https://orcid.org/0000-0002-7235-9990)
- Wouter Huvenne (ORCID: https://orcid.org/0000-0002-0567-8983)
- David Creytens
- Wouter Bauters (ORCID: https://orcid.org/0000-0002-4833-4881)
- Liesbeth Ferdinande (ORCID: https://orcid.org/0009-0008-4030-761X)
- Nick Van Laeken (ORCID: https://orcid.org/0000-0003-1025-3864)
- Jens Debacker (ORCID: https://orcid.org/0000-0002-8293-2885)
Institutions
- HOGENT University of Applied Sciences and Arts (BE)
- Vrije Universiteit Brussel (BE)
- Ghent University Hospital (BE)
- Ghent University (BE)
- AZ Sint-Jan (BE)
- Universitair Ziekenhuis Brussel (BE)
Publication Details
- Journal
- EJNMMI Research
- Published
- 2024-09-12
- DOI
- https://doi.org/10.1186/s13550-024-01148-9
- Citations
- 3
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.07
Funders
- Cancer Research Institute
- Cocoa Research Institute of Ghana